A variety of aurintricarboxylic acid (ATA) polymer analogues were prepared by substituting certain salicylic acid derivatives and carbory; compounds for salicylic acid and formaldehyde in the ATA polymerization reaction. The new polymers were evaluated for prevention of the cytopathic effects of human immunodeficiency virus (HIV-1 and HIV-2) in MT-4 cell culture, HIV-1 in CEM cell culture, and human cytomegalovirus (HCMV) in HEL cell culture. The abilities of the analogues to inhibit syncytium formation between HIV-1-or HIV-2-infected HUT-78 cells and uninfected MOLT-4 cells were also evaluated. Several of the new analogues were found to be equipotent with ATA and dextran sulfate against HIV-1, HIV-2 and HCMV. The anti-HIV potencies of the new substances paralleled their activities against HCMV. The antiviral activities of the new analogues probably result from inhibition of virion binding to the cell membrane.
Introduction
Treatment of salicylic acid with formaldehyde in the presence of sulfuric acid and sodium nitrite results in the formation of a heterogeneous mixture of polymers known as aurintricarboxylic acid (ATA) (Caro et al., 1892; Gonzalez et al., 1979; Cushman and Kanamathareddy, 1990; Cushman et al., 1991b) . The finding that ATA prevents the cytopathic effect of HIV-1 in cell cultures led to mechanism of action studies which revealed that it prevents the initial attachment of virions to cells by inhibiting the bind-ing of gp120 to CD4 (Balzarini et al., 1986; Baba et al., 1988; Schols et al., 1989a Schols et al., , 1990 . ATA has displayed significant activity in a number of biological assays, including inhibition of anti-gp120 monoclonal antibody binding to gp120, inhibition of the binding of the OKT4A monoclonal antibody to the CD4 receptor, inhibition of the attachment of HIV-1 virions to cells, inhibition of syncytium formation, and inhibition of HIV-1 reverse transcriptase (Cushman et al., 1991b) . The determination of the structures of various low-molecular-weight components of ATA and comparison of their NMR spectral data with those of unfractionated ATA led to the schematic representation 1 of the structure of ATA, and the 'ATA monomer' can therefore be portrayed schematically as structure 2 Cushman et al., 1992) (Fig. 1) .
The anti-HIV activity displayed by ATA raises the question of whether or not structurally related polymers would have similar antiviral activities. The answer would provide information about the structural specificity associated with the antiviral effect of ATA and would also be relevant to its mechanism of action. In order to investigate this question, a variety of salicylic acid analogues were reacted with carbonyl compounds in the presence of sulfuric acid and sodium nitrite, and the abilities of the resulting substances to inhibit the HIV-1-and HIV-2-induced cytopathic effect and syncytium formation were determined.The anti-HCMV activities of the analogues were also investigated in HEL cells. The biological activities of the new polymers were compared to those of ATA (1), dextran sulfate (MW 5000) (3) (Ito et al., 1987; Ueno and Kuno 1987) and cosalane (4) (Golebiewski et aI., 1993; Cushman et al., 1994) (Fig. 2 ).
Results
ATA polymer analogues 8,10,12 and 14 were prepared by treating 2,4-dihydroxybenzoic acid (7), thiosalicylic acid (9), 5-hydroxyisophthalic acid (11), and 2,6-dihydroxybenzoic acid (13), respectively, with formaldehyde, sulfuric acid, and sodium nitrite. The reaction times and temperatures were varied as indicated in order to maximize polymer formation. Polymers 16, 18, 20 and 22 were synthesized by reaction of salicylic acid (5) with 2-furaldehyde (15), acrolein (17), butyraldehyde (19) and propionaldehyde (21), respectively, with sulfuric acid and sodium nitrite. For biological testing, the carboxylic acids were converted to their ammonium salts, which were obtained in each case as dark red, brown or black glasses. These substances were characterized by infrared and ultraviolet spectroscopy, as well as by elemental analysis. The detailed results of these analyses are listed in the 'Materials and Experimental Procedures' section.
The anti-HIV activities of the ATA polymer analogues and related substances are listed in Table 1 . All of the new substances were tested for prevention of the cytopathic effect of HIV-1 (strain HTLV-III B ) and HIV-2 (strain LAV-2 RO D ) in MT-4 cells. For prevention of the cytopathic effect of HIV-1 (HTLV-III B ) in MT-4 cells, the most potent of the new analogues was polymer 10 (EC so 0.5 I1g mr'), followed by 8 (EC so 0.7 I1g rnl"), 14 (EC so 0.8 I1g mr'), 18 (EC so 1.6 I1g mr"), 16 (EC so 1.8 I1g rnr"), 22 (EC so 3.8 I1g mr'), 20 (EC so 4.4 I1g ml") and 12 (EC so >250 I1g mr'). The corresponding values for the three standards • 1 were dextran sulfate MW 5000 (3) (EC so 0.03 I1g mr ), ATA (1) (EC so 0.3 I1g rnr'), and cosalane (4) (EC so 1.8~g mr'). The most potent of the new analogues for prevention of the cytopathic effect of HIV-2 (LAV-2 R OO ) in MT-4 cells was 10 (EC so 0.4 I1g mr'), followed by 8 (EC so 1 I1g rnr"), 16 (EC so 1.7 I1g rnl"), 14 (EC so 2.0 I1g mr'), 18 (EC so 2.4 I1g mr'), 22 (EC so 4.9 I1g mr'), 20 (EC so 6.9 I1g ml"), and 12 (EC so >150 I1g mr\ The corresponding values for the three standards were dextran sulfate MW 5000 (3) (EC so 0.04 I1g mr'), ATA (1) (EC so 0.2 I1g mr') and cosalane (4) (EC s04.0 I1g rnl"). The analogues were also tested for prevention of the HIV-1 (strain III B ) cytopathic effect in CEM cells. In that system, polymer analogue 10 (EC so 3.2 I1g ml-1 ) was also the most potent, followed by 18 (EC s05.1 I1g mr'), 8 (EC so 7.3 I1g mr'), 14 (EC so 9.7 I1g mr'), 20 (EC so 14 I1g rnr"), 22 (EC so 24 I1g ml") and 12 (EC so >150 I1g mr'). ATA (1) (EC so 1.2 I1g ml-1 ) and cosalane (4) (EC so 3 I1g mr') were also tested for prevention of the HIV-1 (strain III B ) cytopathic effect in CEM cells. The abilities of the new ATA analogues to inhibit syncytium formation between HIV-1-or HIV-2-infected HUT-78 cells and uninfected MOLT-4 cells were also evaluated. In HIV-1-infected cells, the most potent of the new polymer analogues was 10 (EC so 2 I1g ml"), followed by 8 (EC so 6 I1g mr'), 14 (EC so 10 I1g mr'), 16 (EC so 10 I1g rnr"), 18 (EC so 10 I1g mr"), 20 (EC so 50 I1g "ATA, ATA analogues, and cosalane were tested as their ammonium salts. b The 50% inhibitory concentration, based on the inhibition of the HIV-1-and HIV-2-induced cytopathic effect in MT-4 cells and CEM cells. C The 50% inhibitory concentration, based on the inhibition of syncytium formation between persistently HIV-1-or HIV-2-infected HUT-78 cells and uninfected MOLT-4 (clone 8) cells. d The 50% cytotoxic concentration, based on the reduction of viability of mock-infected MT-4 cells and CEM cells. All data represent mean values ± standard deviation (SO) for at least two separate experiments. The analogues were tested for prevention of the cytopathic effect of HCMV in human embryonic lung (HEL) fibroblasts. The most potent of the new polymer analogues proved to be 8 (EC so 1.1 Jlg ml-1 ) and 10 (EC so 1.1 Jlg mr'), followed by 18 (EC so 2.4 Jlg rnl"), 16 (EC so 5.4 Jlg mr'), 14 (EC so 6.5 Jlg ml"), 22 (EC so 13.4 Jlg rnl"), 20 (EC so 26.5 Jlg mr') and 12 (EC so >100 Jlg rnr'). The minimum toxic concentrations (MTCs) of these compounds in HEL cells were 100 Jlg mr' or more.
Discussion
(EC so 50 Jlg rnl") and 12 (EC so >250 Jlg mr'),The corresponding values for the standards were ATA (1) (EC so 2 Jlg ml'), dexran sulfate MW 5000 (3) (EC so 2 Jlg rnr"), and cosalane (4) (EC so 25 Jlg rnr"). In HIV-2-infected cells, the most potent of the new analogues were 8 (EC so 2 Jlg rnl") and 10 (EC so 2 Jlg mi"), followed by 14 (EC so 6 Jlg rnr"), 18 (EC so 6 Jlg mr'), 16 (EC so 10 Jlg mr'), 20 (EC so 10 Jlg ml- (CC s o 169 Jlg mt") and 12 (CC so>250 Jlg ml"). The corresponding values for the three standards were CC so >125 Jlg rnl" for cosalane (4), cc., >250 Jlg mr' for ATA (1), and CC so >250 Jlg mr' for dextran sulfate MW 5000
(3). In CEM cells, the most cytotoxic of the new polymer analogues was 8 (CC s o 91 Jlg ml"), followed by 14 (CC so 123 Jlg mr'), 20 rcc., 133 Jlg mr'), 18 (CC so 235 Jlg rnr"), 10 rcc., >75 Jlg mr'), 16 (CC so >75 Jlg rnr"), 12 (CC so >150 Jlg mr') and 22 (CC so >250 Jlg mr'), As in MT-4 cells, the CEM cytotoxicities of ATA (1) (CC so >100 Jlg mJ-1 ) and cosalane (4) (CC so >300 Jlg mr') were low.
The anti-human cytomegaloviral (anti-HCMV) activities of the ATA polymer analogues are displayed in Table 2. of polymers. As with ATA, the structures provided for these substances should therefore be considered as simplified schematic representations.
All of the new polymers except 12 displayed some anti-HIV activity as reflected by inhibition of cytopathic effect and inhibition of syncytium formation. Polymer 10, derived from thiosalicylic acid (9), proved to be the most active of the new ATA analogues and was only slightly less potent than ATA. Evidently, the oxygens of the phenolic hydroxyl groups and quinone methide moieties of 1 can be replaced by sulfur without a significant decrease in potency. Polymer 14, resulting from polymerization of 2,6dihydroxybenzoic acid (13), was also only slightly less potent than ATA, showing that additional hydroxyl groups on the rings of 1 are well tolerated. Polymers 16 and 18, having 3-furyl and vinyl substituents on the bridging carbons instead of the salicyl ring of ATA, were less potent. Polymers 20 and 22, having n-propyl and ethyl substituents on the bridging carbon atoms, respectively, were the least potent of the biologically active substances. The replacement of the salicylic acid SU9,ltituents in the bridging carbons on ATA with the various other groups present in 16, 18, 20 and 22 results in a decrease in potency, although some antiviral activity still remains.
Polymer 12 was unique in its total biological inactivity, both as an anti-HIV agent and as a cytotoxic agent. This inactivity may be related to the fact that substance 12 is the only polymer in the series in which the phenolic hydroxyl group or thiol group is not ortho to a carboxyl group.
The results presented in Table 1 also show that the new polymers, in common with dextran sulfate, are up to 5-fold more active against HIV-2-induced syncytium formation than HIV-1-induced syncytium formation. This trend is similar to that previously observed with ATA and various ATA fractions (Cushman et al., 1991b) . Several other antiviral agents are also more active against HIV-2 than HIV-1, including pentosan sulfate (Witvrouw et al., 1990) , dextran sulfate (Witvrouw et al., 1991) , soluble CD4 (Looney et al., 1990) and glycosylation inhibitors (Le. castanospermine) (De Clercq, 1990) . Various polyanionic compounds, inclUding ATA and dextran sulfate samples of low molecular weight (Le. , were found to be more active against HIV-1 or HIV-2, depending on the virus strain and cell type used to assess anti-HIV activity (Witvrouw et al., 1991; Schols et al., 1992) . Negatively charged (i.e, succinylated or aconitylated) human serum albumins are definitely more active against HIV-1 than HIV-2 (Jansen et ei., 1993) ; and the TIBO , HEPT (Baba et ei., 1989) and various other nonnucleoside reverse transcriptase inhibitors (NNRTls) (De Clercq, 1993) are active only against HIV-1 and not at all against HIV-2.
Cosalane (4) was derived conceptually by attaching a Aurintricarboxylic acid VB. HIV and HCMV 183 cholestanyl fragment to a dichlorodisalicylmethane unit 23 (Cushman and Kanamathareddy, 1990; Cushman et al., 1991a) by a three-carbon linker (Golebiewski et al., 1993; Cushman et al., 1994) . As indicated in Table 1 , the ability of cosalane (4) to prevent the cytopathic effect of HIV-1 and HIV-2 in cell cultures is comparable to that of polymeric ATA (1) and the new ATA polymer analogues reported here. In comparison to ATA, however, cosalane (4) offers the advantage of being a structurally defined, low-molecular-weight compound. Both cosalane (4) and ATA (1) are less potent in the present assay systems than MW 5000 dextran sulfate (3). All of the new polymers having anti-HIV activity proved to be more cytotoxic than ATA (1), cosalane (4) and dextran sulfate (3). None of them displayed a particularly favourable therapeutic index relative to ATA (1).
The anti-HIV activity of ATA and various ATA fractions appears to be caused by interference with the gp120-CD4 interaction, resulting in inhibition of virus binding to the cell surface (Schols et el., 1989a; Cushman at al., 1991b) . Assuming that the biological activities of the various polymers reported here are caused by the same mechanism, it can be concluded that the anti-HIV activity of ATA is not associated with a very high degree of structural specificity.
The anti-HCMV actitivies of the analogues are reported in Table 2 , along with the minimum toxic concentrations required to alter normal cell morphology as determined by microscopic examination. ATA polymers are relatively non-toxic for fibroblast cells, and a significant effect of these substances on the growth of HEL cells is only observed for those compounds that also alter cell morphology (Neyts et al., 1992) . Analogues 8 and 10 proved to be the most potent of the new substances against HCMV, which is one of the most important infectious pathogens in immunocompromised hosts (Snoeck et el., 1988) . The potencies of these substances proved to be essentially identical with that of ATA, dextran sulfate and several previously reported poly(hydroxy)carboxylates (Neyts et al., 1992) . The potencies of 8 and 10 were followed by those of 18, 16 and 14. The least potent substances were 22, 20 and the inactive analogue 12. Comparison of the results in Tables 1 and 2 reveals that these relative anti-HCMV potencies closely parallel the activities of the analogues against HIV-1 and HIV-2. We assume that the anti-HCMV activities of these new substances, like those of ATA and related poly(hydroxy)carboxylates, are caused by inhibition of virion attachment to cells, probably resulting from ionic bonding of these polyanions to the positively charged domains of the viral envelope glycoproteins (Neyts et al., 1992) . The therapeutic indexes (ECsolMTC) of 8 and 10 against HCMV were relatively high, indicating the potential therapeutic utilities of these new polymeric substances in treating HCMV infections.
Materials and Experimental Procedures: Chemistry
General procedure for the preparation of the ammonium salts of A TA and A TA analogues Concentrated sulfuric acid (35 ml) was added to a 500-ml, three-necked flask fitted with a mechanical stirrer. The flask was immersed in an ice bath and allowed to stir for 10 min. Sodium nitrite (5.0 g, 72.5 mmol) was added in small portions with stirring for 10 min. Salicylic acid or the salicylic acid analogue (72.4 mmol) was added slowly over 30 min. The reaction flask was removed from the ice water bath and allowed to stir at room temperature for 10 min. Following this, the reaction mixture was cooled again to 0 DC. Formaldehyde solution (37% w/w, 1.96 g, 24.15 mmol) or a carbonyl compound (24.15 mmol) was added dropwise to the cooled solution at such a rate that the addition took 10 min. The reaction mixtures were then stirred for the times and temperatures indicated for each reaction. Crushed ice (about 50 g) was added to the reaction flask along with 2-3 ml of ethyl ether to control foaming. Ice water (about 200 ml) was then added. After stirring at room temperature for 2.5 h, the solution was filtered. The solid material obtained was washed in distilled water (5 x 300 ml), each time for 5 min. Dilute ammonia solution (60 ml, 1 part concentrated NH 40H to 2 parts water) was passed over the filter cake. This converted the solid into a solution of its ammonium salt. The NH a and water were removed by evaporation, and the residue was dried under reduced pressure (1.5 mm) for 24 h at room temperature. The ammonium salts were obtained as dark red, brown, or black glasses. 3568-2346, 1560, 1542, 1458, 1356, 1016, 804, 753, 664, 648, 560 3220-2860, 1560, 1401, 1364, 1306, 1281, 1096,893,886, 796, 777, 725 3588-2346 , 2281 , 1686 , 1654 , 1560 , 1420 , 1086 H, 4.30; N, 11.63 3700-2500 , 1660 , 1560 , 1441 , 1323 , 1086 H, 5.25; N, 11.54 .
ATA analogue 20
UV (H 20) A max (E i r;.') 204 (897), 234 (398), 298 (158) nm; IR (KB~3568-2346 , 2284 ,1686 ,1654 ,1560 ,1490 ,1438 ,1375 , 1252 , 1032 H, 5.58; N, 9.67 .
A TA analogue 22
UV (H 20) A m ax (E\c;.:') 202 (786), 231 (350), 299 (118) nm; IR (KBr) 3630-2350, 1654, 1628, 1560, 1438, 1376, 831, 622 crn". Anal. (ammonium salt) Found: C, 50.44; H, 5.23; N, 10.23.
Materials and Experimental Procedures: Virology

Syncytium formation
This assay is based on syncytium formation and destruction of bystander CD4+ cells (MOLT-4) cocultured with T-cells (HUT-78) persistently infected with HIV-1 (1I1 B ) as demonstrated by flow cytometry (Schols et al., 1989b) .
HIV-infected and uninfected cell viability assay
Cell viability of HIV-infected or uninfected MT-4 cells was quantified by a tetrazolium (MTT) colorimetric method in 96-well microtrays . Cell viability in HIV-1infected and uninfected CEM cells was determined by a tetrazolium (XTT) assay (Weislow et al., 1989) .
Anti-HCMV activity assay
Human embryonic lung (HEL) fibroblasts in 96-well microtitre trays were infected with 100 p.f.u. (plaque-forming units) of virus per well. Compounds were added at the same time as virus, and the cells were further incubated at 37 DC. Virusinduced cytopathic effect was recorded at 7 days as described previously (Snoeck et al., 1988) . Toxicity for uninfected cells was determined microscopically and based on alteration of normal cell morphology.
